Orion and Oriola to continue partnership in Finland
4.9.2023
Orion and Oriola are renewing their distribution agreement in Finland. According to the agreement, Oriola will continue to provide warehousing and distribution services for Orion’s human and veterinary pharmaceuticals in Finland. The new agreement was signed on 29 June 2023, and is effective from 1 July 2024.
The close cooperation of the two Finnish companies will continue to secure quality and timely distribution of pharmaceuticals to the Finnish healthcare sector.
“I’m very pleased with the continuation of our partnership. Oriola and Orion have a long history of working together. As companies we share mutual ambition in enhancing the wellbeing of people, animals and society, as well as strong commitment in promoting sustainability in our operations. This requires strong collaboration in the changing healthcare environment,” says Katarina Gabrielson, CEO of Oriola.
“We are happy to continue our long term cooperation with Oriola in ensuring high-quality delivery services to our customers,” says Janne Maksimainen, Head of Region Finland & Baltics at Orion.
Further information:
Katarina Gabrielson (Oriola)
Email: katarina.gabrielson@oriola.com
Janne Maksimainen (Orion)
Email: janne.maksimainen@orionpharma.com
About Oriola
Oriola aims to be a forerunner in the advanced distribution of pharmaceuticals and in providing advisory services to pharmaceutical companies throughout product lifecycles. In addition, we provide dose dispensing and a wide assortment of health and wellbeing products to pharmacies, veterinarians, retail and other healthcare operators. Our long tradition has set the foundation for our unrivalled knowledge and expertise in the pharmaceutical sector, and to our purpose – Health for life. We take pride in enhancing the availability and safe use of medicines and healthcare products. Oriola operates mainly on Finnish and Swedish markets. In 2022, our net sales were 1.5 billion euros and we employed around 930 professionals. Oriola Corporation is listed on Nasdaq Helsinki. www.oriola.com
About Orion
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.